Fresenius : Conference Call on the acquisition of Ivenix and majority stake in mAbxience (PDF, 1.85 MB)

Conference Call │ Acquisition of Ivenix and majority stake in mAbxience to accelerate strategic growth at Fresenius Kabi

Bad Homburg, 31 March 2022

Safe Harbor Statement

This presentation contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g., changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings the availability of financing, and unforeseen impacts of international conflicts.

Fresenius does not undertake any responsibility to update the forward-looking statements contained in this presentation.

Key messages

Rigorously pursuing our Group growth strategy by allocating growth capital to most attractive marketsRebalancing of Fresenius Group portfolio towards a higher relative weight of attractive product businessRisk-mitigated and balance sheet supporting deal structures

First steps in executing

Fresenius Kabi's "Vision 2026" growth strategyAccelerating strategic growth whilst safeguarding previous investmentsAcquisition of mAbxience stake significantly enhances Fresenius Kabi's presence in high-growth biopharma marketAcquisition of Ivenix adds next-generation infusion therapy platform to transform product offeringAcquisitions combined are broadly neutral to Group cash earnings in 2022 and accretive from 2023